NCT06506916View on ClinicalTrials.gov

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

March 9, 2027

Study Completion Date

March 14, 2028

Conditions
Moderate to Severe Plaque PsoriasisPsoriatic Arthritis
Interventions
DRUG

bimekizumab

Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.

Trial Locations (16)

14623

RECRUITING

Ps0039 50643, Rochester

15213

RECRUITING

Ps0039 50491, Pittsburgh

33613

RECRUITING

Ps0039 50283, Tampa

35233

RECRUITING

Ps0039 50140, Birmingham

48109

RECRUITING

Ps0039 50110, Ann Arbor

90404

SUSPENDED

Ps0039 50642, Santa Monica

92708

RECRUITING

Ps0039 50162, Fountain Valley

Unknown

RECRUITING

Ps0039 40515, Berlin

RECRUITING

Ps0039 40287, Frankfurt am Main

RECRUITING

Ps0039 40072, Freiburg im Breisgau

RECRUITING

Ps0039 40775, Witten

RECRUITING

Ps0039 40347, Lodz

RECRUITING

Ps0039 40625, Lodz

RECRUITING

Ps0039 40757, Poznan

RECRUITING

Ps0039 40761, Warsaw

RECRUITING

Ps0039 40773, Wroclaw

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY